Deripapa Elena, Balashov Dmitry, Rodina Yulia, Laberko Alexandra, Myakova Natalya, Davydova Nataliia V, Gordukova Maria A, Abramov Dmitrii S, Pay Galina V, Shelikhova Larisa, Prodeus Andrey P, Maschan Mikhail A, Maschan Alexey A, Shcherbina Anna
Dmitry Rogachev National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Speransky Children's Hospital, Moscow, Russia.
Front Immunol. 2017 Jul 24;8:807. doi: 10.3389/fimmu.2017.00807. eCollection 2017.
Nijmegen breakage syndrome (NBS) is a combined primary immunodeficiency with DNA repair defect, microcephaly, and other phenotypical features. It predominantly occurs in Slavic populations that have a high frequency of carriers with the causative NBN gene c.657_661del5 mutation. Due to the rarity of the disease in the rest of the world, studies of NBS patients are few. Here, we report a prospective study of a cohort of Russian NBS patients.
35 Russian NBS patients of ages 1-19 years, referred to our Center between years 2012 and 2016, were prospectively studied.
Despite the fact that in 80% of the patients microcephaly was diagnosed at birth or shortly thereafter, the average delay of NBS diagnosis was 6.5 years. Though 80% of the patients had laboratory signs of immunodeficiency, only 51% of the patients experienced significant infections. Autoimmune complications including interstitial lymphocytic lung disease and skin granulomas were noted in 34%, malignancies-in 57% of the patients. T-cell excision circle (TREC)/kappa-deleting recombination excision circle (KREC) levels were low in the majority of patients studied. Lower KREC levels correlated with autoimmune and oncological complications. Fifteen patients underwent hematopoietic stem cell transplantation (HSCT), 10 of them were alive and well, with good graft function. Three patients in the HSCT group and five non-transplanted patients died; tumor progression being the main cause of death. The probability of the overall survival since NBS diagnosis was 0.76 in the HSCT group and 0.3 in the non-transplanted group.
Based on our findings of low TRECs in most NBS patients, independent of their age, TREC detection can be potentially useful for detection of NBS patients during neonatal screening. KREC concentration can be used as a prognostic marker of disease severity. HSCT is a viable treatment option in NBS and should be especially considered in patients with low KREC numbers early on, before development of life-threatening complications.
奈梅亨断裂综合征(NBS)是一种伴有DNA修复缺陷、小头畸形及其他表型特征的原发性联合免疫缺陷病。该病主要发生在斯拉夫人群中,其携带致病NBN基因c.657_661del5突变的频率较高。由于在世界其他地区该病较为罕见,对NBS患者的研究较少。在此,我们报告一项针对俄罗斯NBS患者队列的前瞻性研究。
对2012年至2016年间转诊至我们中心的35例年龄在1至19岁的俄罗斯NBS患者进行前瞻性研究。
尽管80%的患者在出生时或出生后不久即被诊断为小头畸形,但NBS诊断的平均延迟时间为6.5年。虽然80%的患者有免疫缺陷的实验室指标,但只有51%的患者经历过严重感染。34%的患者出现自身免疫并发症,包括间质性淋巴细胞性肺病和皮肤肉芽肿,57%的患者发生恶性肿瘤。在大多数研究患者中,T细胞切除环(TREC)/κ链缺失重组切除环(KREC)水平较低。较低的KREC水平与自身免疫和肿瘤并发症相关。15例患者接受了造血干细胞移植(HSCT),其中10例存活且状况良好,移植功能良好。HSCT组有3例患者和5例未移植患者死亡;肿瘤进展是主要死因。HSCT组自NBS诊断后的总生存率为0.76,未移植组为0.3。
基于我们在大多数NBS患者中发现的低TREC水平(与年龄无关),TREC检测在新生儿筛查期间可能有助于检测NBS患者。KREC浓度可作为疾病严重程度的预后标志物。HSCT是NBS的一种可行治疗选择,对于KREC数量低的患者,应在危及生命的并发症出现之前尽早特别考虑。